Details of the Drug

General Information of Drug (ID: DM3P5DA)

Drug Name
Rofecoxib
Synonyms
Ceoxx; Refecoxib; Vioxx; Cahill May Roberts brand of rofecoxib; MSD brand of rofecoxib; Merck Frosst brandof rofecoxib; Merck brand of rofecoxib; Vioxx Dolor; MK 0966; MK 0996; MK 966; MK0966; Ceeoxx (TN); Ceoxx (TN); KS-1107; MK-0966; MK-966; Merck Sharp & Dhome brand of rofecoxib; Vioxx (TN); Vioxx (trademark); Rofecoxib (JAN/USAN/INN); 3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one; 3-Phenyl-4-(4-(methylsulfonyl)phenyl))-2(5H)-furanone; 3-phenyl-4-[4-(methylsulfonyl)phenyl]-2(5H)-furanone; 4-(4-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 4-(4-methylsulfonylphenyl)-3-phenyl-5H-furan-2-one; 4-(p-(Methylsulfonyl)phenyl)-3-phenyl-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenyl-2(5H)-furanone; 4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one
Indication
Disease Entry ICD 11 Status REF
Osteoarthritis FA00-FA05 Approved [1], [2]
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 314.4
Topological Polar Surface Area (xlogp) 2.3
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 93% [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 2 mL/min/kg [5]
Elimination
1% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 17 hours [5]
Metabolism
The drug is metabolized via the hepatic [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.64981 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.13% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.3 L/kg [5]
Water Solubility
The ability of drug to dissolve in water is measured as 0.1 mg/mL [3]
Chemical Identifiers
Formula
C17H14O4S
IUPAC Name
3-(4-methylsulfonylphenyl)-4-phenyl-2H-furan-5-one
Canonical SMILES
CS(=O)(=O)C1=CC=C(C=C1)C2=C(C(=O)OC2)C3=CC=CC=C3
InChI
InChI=1S/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3
InChIKey
RZJQGNCSTQAWON-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5090
ChEBI ID
CHEBI:8887
CAS Number
162011-90-7
DrugBank ID
DB00533
TTD ID
D05VLS
VARIDT ID
DR00753
INTEDE ID
DR1433

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [7], [8], [9], [10], [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [13]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [14]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [15]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Osteoarthritis
ICD Disease Classification FA00-FA05
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 2 (COX-2) DTT PTGS2 7.93E-04 -0.29 -0.34
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 1.82E-04 -1.35E-01 -5.84E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 7.36E-01 1.62E-02 1.08E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Prostaglandin G/H synthase 1 (COX-1) DME PTGS1 3.97E-03 1.56E-01 4.33E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Rofecoxib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Diclofenac DMPIHLS Moderate Increased risk of hepatotoxicity by the combination of Rofecoxib and Diclofenac. Osteoarthritis [FA00-FA05] [57]
Coadministration of a Drug Treating the Disease Different from Rofecoxib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Rofecoxib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [58]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Rofecoxib and Repaglinide. Acute diabete complication [5A2Y] [59]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Rofecoxib and Glibenclamide. Acute diabete complication [5A2Y] [59]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Rofecoxib and Tolazamide. Acute diabete complication [5A2Y] [60]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Rofecoxib and Nateglinide. Acute diabete complication [5A2Y] [59]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Rofecoxib and Glipizide. Acute diabete complication [5A2Y] [59]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Rofecoxib and Inotersen. Amyloidosis [5D00] [61]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Rofecoxib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [62]
Budesonide DMJIBAW Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Rofecoxib and Budesonide. Asthma [CA23] [63]
Aminophylline DML2NIB Moderate Decreased metabolism of Rofecoxib caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [64]
Ofloxacin DM0VQN3 Moderate Additive CNS stimulant effects by the combination of Rofecoxib and Ofloxacin. Bacterial infection [1A00-1C4Z] [65]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Rofecoxib and Kanamycin. Bacterial infection [1A00-1C4Z] [66]
Ciprofloxacin XR DM2NLS9 Moderate Additive CNS depression effects by the combination of Rofecoxib and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [65]
Trovafloxacin DM6AN32 Moderate Additive CNS stimulant effects by the combination of Rofecoxib and Trovafloxacin. Bacterial infection [1A00-1C4Z] [67]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Rofecoxib and Streptomycin. Bacterial infection [1A00-1C4Z] [66]
Gemifloxacin DMHT34O Moderate Additive CNS depression effects by the combination of Rofecoxib and Gemifloxacin. Bacterial infection [1A00-1C4Z] [65]
Norfloxacin DMIZ6W2 Moderate Additive CNS stimulant effects by the combination of Rofecoxib and Norfloxacin. Bacterial infection [1A00-1C4Z] [67]
ABT-492 DMJFD2I Moderate Additive CNS depression effects by the combination of Rofecoxib and ABT-492. Bacterial infection [1A00-1C4Z] [65]
Gentamicin DMKINJO Moderate Increased risk of nephrotoxicity by the combination of Rofecoxib and Gentamicin. Bacterial infection [1A00-1C4Z] [66]
Levofloxacin DMS60RB Moderate Additive CNS stimulant effects by the combination of Rofecoxib and Levofloxacin. Bacterial infection [1A00-1C4Z] [65]
Tobramycin DMUI0CH Moderate Increased risk of nephrotoxicity by the combination of Rofecoxib and Tobramycin. Bacterial infection [1A00-1C4Z] [66]
Etidronic acid DM1XHYJ Moderate Increased risk of nephrotoxicity by the combination of Rofecoxib and Etidronic acid. Bone paget disease [FB85] [68]
Risedronate DM5FLTY Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Rofecoxib and Risedronate. Bone paget disease [FB85] [68]
Alendronate DMY2KX9 Moderate Increased risk of nephrotoxicity by the combination of Rofecoxib and Alendronate. Bone paget disease [FB85] [68]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Rofecoxib and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [69]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Rofecoxib and Drospirenone. Contraceptive management [QA21] [70]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Rofecoxib and Cannabidiol. Epileptic encephalopathy [8A62] [61]
Ethacrynic acid DM60QMR Moderate Antagonize the effect of Rofecoxib when combined with Ethacrynic acid. Essential hypertension [BA00] [71]
Eplerenone DMF0NQR Moderate Antagonize the effect of Rofecoxib when combined with Eplerenone. Heart failure [BD10-BD1Z] [72]
Chlorothiazide DMLHESP Moderate Antagonize the effect of Rofecoxib when combined with Chlorothiazide. Heart failure [BD10-BD1Z] [71]
Furosemide DMMQ8ZG Moderate Antagonize the effect of Rofecoxib when combined with Furosemide. Heart failure [BD10-BD1Z] [71]
Amiloride DMRTSGP Moderate Antagonize the effect of Rofecoxib when combined with Amiloride. Heart failure [BD10-BD1Z] [71]
Bumetanide DMRV7H0 Moderate Antagonize the effect of Rofecoxib when combined with Bumetanide. Heart failure [BD10-BD1Z] [71]
Hydroflumethiazide DMVPUQI Moderate Antagonize the effect of Rofecoxib when combined with Hydroflumethiazide. Heart failure [BD10-BD1Z] [71]
Rifampin DMA8J1G Moderate Increased metabolism of Rofecoxib caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [73]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Rofecoxib and Brentuximab vedotin. Hodgkin lymphoma [2B30] [74]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Rofecoxib and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [75]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Rofecoxib and Mipomersen. Hyper-lipoproteinaemia [5C80] [76]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Rofecoxib and Teriflunomide. Hyper-lipoproteinaemia [5C80] [77]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Rofecoxib and BMS-201038. Hyper-lipoproteinaemia [5C80] [78]
Captopril DM458UM Moderate Antagonize the effect of Rofecoxib when combined with Captopril. Hypertension [BA00-BA04] [72]
Indapamide DMGN1PW Moderate Antagonize the effect of Rofecoxib when combined with Indapamide. Hypertension [BA00-BA04] [71]
Hydrochlorothiazide DMUSZHD Moderate Antagonize the effect of Rofecoxib when combined with Hydrochlorothiazide. Hypertension [BA00-BA04] [79]
Fludrocortisone DMUDIR8 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Rofecoxib and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [63]
Ramelteon DM7IW9J Moderate Decreased metabolism of Rofecoxib caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [80]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Rofecoxib caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [81]
Alosetron DML2A03 Moderate Decreased metabolism of Rofecoxib caused by Alosetron mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [82]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Rofecoxib and Methotrexate. Leukaemia [2A60-2B33] [61]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Rofecoxib caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [83]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Rofecoxib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [84]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Rofecoxib and Idelalisib. Mature B-cell leukaemia [2A82] [85]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Rofecoxib and Clofarabine. Mature B-cell lymphoma [2A85] [61]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Rofecoxib and Exjade. Mineral absorption/transport disorder [5C64] [86]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Rofecoxib and Deflazacort. Muscular dystrophy [8C70] [63]
Polythiazide DMCH80F Moderate Antagonize the effect of Rofecoxib when combined with Polythiazide. Oedema [MG29] [71]
Aspirin DM672AH Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Rofecoxib and Aspirin. Pain [MG30-MG3Z] [87]
Rasagiline DM3WKQ4 Moderate Decreased metabolism of Rofecoxib caused by Rasagiline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [58]
Prednisone DM2HG4X Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Rofecoxib and Prednisone. Postoperative inflammation [1A00-CA43] [63]
Hydrocortisone DMGEMB7 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Rofecoxib and Hydrocortisone. Postoperative inflammation [1A00-CA43] [63]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Rofecoxib and Everolimus. Renal cell carcinoma [2C90] [88]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Rofecoxib and Temsirolimus. Renal cell carcinoma [2C90] [88]
Gatifloxacin DMSL679 Moderate Additive CNS stimulant effects by the combination of Rofecoxib and Gatifloxacin. Respiratory infection [CA07-CA4Z] [67]
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Rofecoxib and Sulfasalazine. Rheumatoid arthritis [FA20] [89]
Dexamethasone DMMWZET Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Rofecoxib and Dexamethasone. Rheumatoid arthritis [FA20] [63]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Rofecoxib and Leflunomide. Rheumatoid arthritis [FA20] [77]
Asenapine DMSQZE2 Moderate Decreased metabolism of Rofecoxib caused by Asenapine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [90]
Pimozide DMW83TP Moderate Decreased metabolism of Rofecoxib caused by Pimozide mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [91]
Methylprednisolone DM4BDON Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Rofecoxib and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [63]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Rofecoxib and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [61]
Prednisolone DMQ8FR2 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Rofecoxib and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [63]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Rofecoxib and Naltrexone. Substance abuse [6C40] [92]
Tizanidine DMR2IQ4 Major Decreased metabolism of Rofecoxib caused by Tizanidine mediated inhibition of CYP450 enzyme. Tonus and reflex abnormality [MB47] [93]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Rofecoxib and Sirolimus. Transplant rejection [NE84] [88]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Rofecoxib and Tacrolimus. Transplant rejection [NE84] [88]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Rofecoxib and Tolbutamide. Type 2 diabetes mellitus [5A11] [60]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Rofecoxib and Chlorpropamide. Type 2 diabetes mellitus [5A11] [60]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Rofecoxib and Olsalazine. Ulcerative colitis [DD71] [89]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Rofecoxib and Plazomicin. Urinary tract infection [GC08] [94]
Triamcinolone DM98IXF Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Rofecoxib and Triamcinolone. Vasomotor/allergic rhinitis [CA08] [63]
⏷ Show the Full List of 79 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2893).
2 New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs. 2008 Aug;17(8):1187-202.
3 BDDCS applied to over 900 drugs
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
8 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
9 Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
10 The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology. 2003 Sep;125(3):716-29.
11 Clinical experience with cyclooxygenase-2 inhibitors. Rheumatology (Oxford). 2002 Apr;41 Supp 1:16-22; discussion 35-42.
12 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
13 Impact of CYP2C9 genotype on pharmacokinetics: are all cyclooxygenase inhibitors the same? Drug Metab Dispos. 2005 Nov;33(11):1567-75.
14 Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol. 2006 Sep;62(3):345-57.
15 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
16 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
17 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
18 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
19 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
20 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
21 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
22 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
23 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
24 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
25 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
26 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
27 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
28 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
29 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
30 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
31 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
32 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
33 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
34 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
35 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
36 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
37 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
38 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
39 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
40 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
41 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
42 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
43 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
44 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
45 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
46 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
47 Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
48 Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
49 Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
50 Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
51 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
52 Pfizer. Product Development Pipeline. March 31 2009.
53 Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
54 Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
55 Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
56 Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice. Eur Respir J. 2009 Jul;34(1):200-8.
57 Product Information. Solaraze (diclofenac topical). Doak Dermatologics Division, Fairfield, NJ.
58 Cerner Multum, Inc. "Australian Product Information.".
59 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
60 Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
61 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
62 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
63 Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
64 Product Information. Vioxx (rofecoxib). Merck & Co, Inc, West Point, PA.
65 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
66 Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
67 Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
68 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
69 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
70 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
71 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
72 Abdel-Haq B, Magagna A, Favilla S, Salvetti A "Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects." J Cardiovasc Pharmacol 18 (1991): s33-6. [PMID: 1725198]
73 Product Information. Vioxx (rofecoxib). Merck &amp Co, Inc, West Point, PA.
74 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
75 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
76 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
77 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
78 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
79 McCarthy JT, Torres VE, Romero JC, et al "Acute intrinsic renal failure induced by indomethacin." Mayo Clin Proc 57 (1982): 289-96. [PMID: 6952058]
80 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
81 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
82 Product Information. Lotronex (alosetron). Glaxo Wellcome, Research Triangle Park, NC.
83 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
84 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
85 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
86 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
87 Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
88 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
89 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
90 Product Information. Saphris (asenapine). Schering-Plough Corporation, Kenilworth, NJ.
91 Krahenbuhl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ "Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication." Am J Med Sci 309 (1995): 315-6. [PMID: 7771501]
92 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
93 Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro." Br J Clin Pharmacol 57 (2004): 349-53. [PMID: 14998432]
94 Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S "Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium." Clin Sci 91 (1996): 187-91. [PMID: 8795442]